What you're looking at is not the Weight Watchers in the historical filings.

• The wipeout. A prepackaged Chapter 11 filed May 6, 2025 and emerged June 24, 2025 discharged $1.6B of pre-petition debt. Old common stock was canceled at 1-for-93 into 10M new shares — pre-petition holders ended up with roughly 9% of the post-emergence equity.
• The new capital structure. A single $465M term loan due 2030 replaced the prior $1.1B credit facility plus $500M of senior notes. Net debt fell from $1.43B to $308M; equity flipped from −$4.1B to +$318M. Cleanest balance sheet in 20 years.
• The new owners and the empty chair. Brigade Capital and other former bondholders now control the cap table; five of seven directors are new. CEO Tara Comonte exited March 31, 2026 — the third CEO departure in three years — leaving an Office of the CEO under the CFO and COO.

Behavioral is melting at 250–400K subs a year. Clinical adds 55K. The pivot can't outrun the melt at this slope.

Clinical members pay roughly 5× Behavioral ARPU because Med+ bundles a GLP-1 prescription. The consolidated math is unforgiving: doubling Clinical to 260K adds about $60M, while a 12% Behavioral decay on the larger base subtracts about $90M. Management's own FY2026 guide ($620–635M revenue, $105–115M EBITDA) concedes another year of decline; the question is whether the slope inflects before the term loan matures in 2030.

Q1 FY2026 earnings on May 7 deploy 40–45% of the full-year marketing budget in a single quarter.

• The setup. Management front-loaded nearly half of FY2026 marketing spend to push Clinical from ~130K toward a self-set 200K target, then reaffirmed the $620–635M revenue / $105–115M EBITDA guide on April 3 — alongside the CEO exit announcement.
• The bull read. Clinical at 175K+ with Behavioral attrition decelerating below 12% YoY and the FY26 guide held without caveat. That re-rates the equity toward 6× peer EV/EBITDA on $110M — a $20-plus range, more than 2× today.
• The bear read. Clinical under 160K, Behavioral attrition 15%-plus, or any guide trim. Sell-side cuts EBITDA toward $80M; a Q2 impairment against the freshly written-up $529M Successor intangibles base re-prices the equity off a smaller asset base.

May 7 isn't the real proving event — August is.

• The Q1 print is engineered. Loading 40–45% of the FY marketing budget into one quarter to hit a self-set Clinical target is a setup designed to look defensible. Q2 — when marketing falls back to ~15% of the FY budget — tests whether subscribers were earned or rented.
• Adjusted EBITDA flatters reality. The bridge backs out a fourth consecutive year of 'non-recurring' restructuring (~$20M annualized), and capex sits at $0.1M against $107M of annualized Successor amortization. Cash-like EBITDA is closer to $80–90M, not $110M.
• The Brigade buy isn't what bulls think. Carney Hawks' $643K open-market purchase at $22.14 is a 0.3% top-up to a creditor-converted majority stake. Brigade's blended basis is bond-recovery economics — roughly $11/share effective, not the open-market price.